Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 750 of 2051 entries
View as:

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

Phase: N/A Priority: Normal
NCT ID: NCT06655324 Org: User:
Start: 12/05/24 End: 11/21/26 Due: 11/21/27

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Phase: N/A Priority: Normal
NCT ID: NCT05562830 Org: User:
Start: 11/16/22 End: 05/08/28 Due: 05/08/29

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Phase: N/A Priority: Normal
NCT ID: NCT00443846 Org: User:
Start: 02/13/07 End: 10/23/07 Due: 10/23/08

MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)

Phase: N/A Priority: Normal
NCT ID: NCT00543868 Org: User:
Start: 06/30/04 End: 08/31/04 Due: 08/31/05

A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00971633 Org: User:
Start: 11/30/03 End: 01/31/04 Due: 01/31/05

[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Phase: N/A Priority: Normal
NCT ID: NCT02562989 Org: User:
Start: 10/19/15 End: 12/27/16 Due: 12/27/17

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00565006 Org: User:
Start: 07/31/06 End: 09/30/06 Due: 09/30/07

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Phase: N/A Priority: Normal
NCT ID: NCT00750178 Org: User:
Start: 11/01/04 End: 11/01/05 Due: 11/01/06

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

Phase: N/A Priority: Normal
NCT ID: NCT01000818 Org: User:
Start: 06/30/08 End: 03/31/09 Due: 03/31/10

A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)

Phase: N/A Priority: Normal
NCT ID: NCT01628042 Org: User:
Start: 07/16/12 End: 01/25/13 Due: 01/25/14

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)

Phase: N/A Priority: Normal
NCT ID: NCT06797674 Org: User:
Start: 02/10/25 End: 08/12/25 Due: 08/12/26

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)

Phase: N/A Priority: Normal
NCT ID: NCT02105688 Org: User:
Start: 09/02/14 End: 12/04/18 Due: 12/04/19

A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00092378 Org: User:
Start: 09/01/03 End: 12/01/03 Due: 12/01/04

GARDASIL™ Vaccine Impact in Population Study (V501-033)

Phase: N/A Priority: Normal
NCT ID: NCT01077856 Org: User:
Start: 05/29/07 End: 12/02/14 Due: 12/02/15

Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

Phase: N/A Priority: Normal
NCT ID: NCT02133131 Org: User:
Start: 06/13/14 End: 02/01/16 Due: 02/01/17

A Single Dose Study of MK-8266 (MK-8266-001)

Phase: N/A Priority: Normal
NCT ID: NCT01025791 Org: User:
Start: 11/18/09 End: 05/14/10 Due: 05/14/11

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Phase: N/A Priority: Normal
NCT ID: NCT01905657 Org: User:
Start: 08/09/13 End: 09/30/20 Due: 09/30/21

V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)

Phase: N/A Priority: Normal
NCT ID: NCT05450705 Org: User:
Start: 07/22/22 End: 08/03/29 Due: 08/03/30

Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

Phase: N/A Priority: Normal
NCT ID: NCT01932762 Org: User:
Start: 10/01/13 End: 12/04/14 Due: 12/04/15

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Phase: N/A Priority: Normal
NCT ID: NCT01425203 Org: User:
Start: 11/23/11 End: 10/21/13 Due: 10/21/14

A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)

Phase: N/A Priority: Normal
NCT ID: NCT01015677 Org: User:
Start: 12/17/09 End: 07/30/10 Due: 07/30/11

A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)

Phase: N/A Priority: Normal
NCT ID: NCT00849732 Org: User:
Start: 06/30/03 End: 02/28/11 Due: 02/28/12

A Study of V950 in People With Alzheimer Disease (V950-001 AM7)

Phase: N/A Priority: Normal
NCT ID: NCT00464334 Org: User:
Start: 03/31/07 End: 01/31/12 Due: 01/31/13

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Phase: N/A Priority: Normal
NCT ID: NCT03217136 Org: User:
Start: 04/03/18 End: 03/16/20 Due: 03/16/21

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00035282 Org: User:
Start: 09/30/01 End: 12/31/03 Due: 12/31/04